» Authors » Raymond L Stallings

Raymond L Stallings

Explore the profile of Raymond L Stallings including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 2867
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Miller-Delaney S, Bryan K, Das S, McKiernan R, Bray I, Reynolds J, et al.
Brain . 2015 Jan; 138(Pt 3):616-31. PMID: 25552301
Temporal lobe epilepsy is associated with large-scale, wide-ranging changes in gene expression in the hippocampus. Epigenetic changes to DNA are attractive mechanisms to explain the sustained hyperexcitability of chronic epilepsy....
12.
Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini G, et al.
PLoS One . 2014 Dec; 9(12):e114696. PMID: 25502557
Background: Neuroblastoma is a pediatric cancer that exhibits a wide clinical spectrum ranging from spontaneous regression in low-risk patients to fatal disease in high-risk patients. The identification of single nucleotide...
13.
Lee S, Rahnenfuhrer J, Lang M, De Preter K, Mestdagh P, Koster J, et al.
PLoS One . 2014 Oct; 9(10):e108818. PMID: 25295525
Identifying relevant signatures for clinical patient outcome is a fundamental task in high-throughput studies. Signatures, composed of features such as mRNAs, miRNAs, SNPs or other molecular variables, are often non-overlapping,...
14.
Harvey H, Piskareva O, Creevey L, Alcock L, Buckley P, OSullivan M, et al.
Int J Cancer . 2014 Aug; 136(7):1579-88. PMID: 25137037
The acquisition of multidrug resistance is a major impediment to the successful treatment of neuroblastoma, a clinically heterogeneous cancer accounting for ∼15% of all pediatric cancer deaths. The MYCN transcription...
15.
Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, et al.
Pediatr Blood Cancer . 2014 Jan; 61(10):1867-70. PMID: 24391119
While a polymorphism located within the promoter region of the MDM2 proto-oncogene, SNP309 (T > G), has previously been associated with increased risk and aggressiveness of neuroblastoma and other tumor...
16.
Bryan K, Terrile M, Bray I, Domingo-Fernandez R, Watters K, Koster J, et al.
Nucleic Acids Res . 2013 Dec; 42(3):e17. PMID: 24357407
MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression at a post-transcriptional level. An miRNA may target many messenger RNA (mRNA) transcripts, and each transcript may be targeted...
17.
Lynch J, Meehan M, Crean J, Copeland J, Stallings R, Bray I
PLoS One . 2013 Nov; 8(11):e78428. PMID: 24223803
MiRNAs can have pleiotropic effects by targeting multiple genes belonging to diverse signalling networks. Alternatively, miRNAs can enhance the potency of their cellular effects by targeting multiple genes within the...
18.
Miller-Delaney S, Das S, Stallings R, Henshall D
Methods Mol Biol . 2013 Aug; 1067:87-101. PMID: 23975788
Epigenetic modification of DNA by methylation of the cytosine present in CG dinucleotides constitutes a key regulatory mechanism in the control of gene expression in neurological diseases. In this chapter,...
19.
Wilzen A, Krona C, Sveinbjornsson B, Kristiansson E, Dalevi D, Ora I, et al.
Mol Cancer . 2013 Jul; 12(1):70. PMID: 23835063
Background: Neuroblastoma (NB) tumours are commonly divided into three cytogenetic subgroups. However, by unsupervised principal components analysis of gene expression profiles we recently identified four distinct subgroups, r1-r4. In the...
20.
Watters K, Bryan K, Foley N, Meehan M, Stallings R
BMC Cancer . 2013 Apr; 13:184. PMID: 23565812
Background: Ultra-conserved regions (UCRs) are segments of the genome (≥ 200 bp) that exhibit 100% DNA sequence conservation between human, mouse and rat. Transcribed UCRs (T-UCRs) have been shown to...